Background: Recent evidence indicates that acute stress can precipitate a number of dermatological conditions, including alopecia areata. This effect may be mediated by corticotropin-releasing hormone (CRH) released locally in the skin from dorsal root ganglia or immune cells. CRH typically acts through activation of specific receptors that are either type 1 or types 2α and 2β. CRH, or related peptides such as urocortin, could have proinflammatory effects directly or through activation of mast cells leading to destruction of the hair root. Objectives: To investigate the expression of CRH receptors on the affected skin of patients who developed alopecia areata following acute emotional stress. Methods: Scalp skin biopsies were obtained from 1 normal volunteer and 3 patients after ring infiltration of the relevant site with lidocaine. The biopsies were frozen and were later processed for in situ hybridization for CRH receptors type 1 or types 2α and 2β. Sections showing positive results were photographed. Results: The skin from the normal volunteer showed weak background expression of all three receptor types. However, skin from the affected sites of all 3 patients studied showed intense expression only on the type 2β receptor around the hair follicles. Conclusion: Acute emotional stress may precipitate alopecia areata by activation of overexpressed type 2β CRH receptors around the hair follicles leading to intense local inflammation.

Keywords:
Alopecia, Corticotropin-releasing hormone, Mast cells, Inflammation, Stress
1.
Rabkin JG, Struening EL: Life events, stress and illness. Science 1976;194:1013–1020.
2.
Sternberg EM, Chrousos GP, Wilder RL, Gold PW: The stress response and the regulation of inflammatory disease. Ann Intern Med 1992;117:854–866.
3.
Wallengren J, Ekman R, Moller H: Substance P and vasoactive intestinal peptide in bullous and inflammatory skin disease. Acta Derm Venereol (Stockh) 1986;66:23–28.
4.
Rabier MJ, Farber EM, Wilkinson DI: Neuropeptides modulate leukotriene R4 mitogenicity toward cultured human keratinocytes. J Invest Dermatol 1993;100:132–136.
5.
Williams K, Bienenstock J, Perdue MH: The role of psychological and neurological factors in allergic reactions. ACI News 1992;4/3:77–85.
6.
Orfan NA, Kolski GB: Physical urticarias. Ann Allergy 1993;71:205–216.
7.
Van Moffaert M: Psychodermatology: An overview: Psychother Psychosom 1992;58:125–136.
8.
Reichlin S: Neuroendocrine-immune interactions. N Engl J Med 1993;329:1246–1253.
9.
Champion RH, Parish WE: Atopic dermatitis; in Rook A, Wilkinson DS, Ebling FJG (ed): Textbook of Dermatology ed 3. Philadelphia, Blackwell, 1979, pp 349–361.
10.
De Waard-Vanderspek FB, Orange AP, De Raeymaecker DM, Peereboom-Wynia JD: Juvenile versus maturity-onset alopecia areata – A comparative retrospective clinical study. Clin Exp Dermatol 1989;14:429–433.
11.
Chrousos GP: The hypothalamic-pituitary- adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351–1362.
12.
Lovenberg TW, Chalmers DT, Liu C, DeSouza EB: CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995;136:4139–4142.
13.
Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421–423.
14.
Karalis K, Louis JM, Bae D, Hilderbrand H, Majzoub JA: CRH and the immune system. J Neuroimmunol 1997;72:131–136.
15.
Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403–413.
16.
Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC: Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders. Brain Behav Immun 1999;13:225–239.
17.
Jaworsky C, Kligman AM, Murphy GF: Characterization of inflammatory infiltrates in male pattern alopecia: Implications for pathogenesis: Br J Dermatol 1992;127:239–246.
18.
Friedman PS: Alopecia areata and autoimmunity. Br J Dermatol 1981;105:153–157.
19.
Muller SA, Winkelmann RK: Alopecia areata. Arch Dermatol 1963;88:290–297.
20.
Bertolino AP: Alopecia areata: A clinical overview. Postgrad Med 2000;107:81–90.
21.
Lattanand A, Johnson WC: Male pattern alopecia: A histopathologic and histochemical study. J Cutan Pathol 1975;2:58–70.
22.
Okun MR, Donnellan B: Ultrastructural relationship of melanocytes to mast cells and ‘melanophages’ in a lesion of alopecia mucinosa. J Invest Dermatol 1972;59:211–224.
23.
Tonii T, Okada T, Fukai K, Nakagawa K, Hamada T: Increase of mast cells in the alopecia lesion of mice. Derm Venereol (Stockh) 1985;65:64–66.
24.
Christoph T, Muller-Rover S, Audring H, Tobin DJ, Hermes B, Cotsarelis G, Ruckert R, Paus R: The human hair follicle immune system: Cellular composition and immune privilege. Br J Dermatol 2000;142:862–873.
25.
Sueki H, Stoudemayer T, Kligman AM, Murphy GF: Quantitative and ultrastructural analysis of inflammatory infiltrates in male pattern alopecia. Acta Derm Venereol (Stockh) 1999;79:347–350.
26.
Walker SA, Rothman S: Alopecia areata: A statistical study and consideration of endocrine influences. J Invest Dermatol 1950;14:403–412.
27.
Klein U, Weinheimer B, Faun H: Simultaneous occurrence of alopecia areata and immunothyroiditis. Int J Dermatol 1974;13:116–118.
28.
Thompson DM: Alopecia areata, vitiligo, scleroderma and ulcerative colitis. Proc R Soc Med 1974;67:1010–1012.
29.
Schenk EAE: Autoantibodies in alopecia and vitiligo in hair; in Brown AC, Crounse RG (eds): Trace Elements and Human Illness. New York, Praeger, 1980, p 334.
30.
Gupta MA, Gupta AK, Watteel GN: Stress and alopecia areata: A psychodermatologic study. Acta Derm Venereol (Stockh) 1997;77:296–298.
31.
Katsarou-Katsari A, Filippou A, Theoharides TC: Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol 1999;12:7–11.
32.
Singh LK, Boucher W, Pang X, Letourneau R, Seretakis D, Green M, Theoharides TC: Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors. J Pharmacol Exp Ther 1999;288:1349–1356.
33.
Slominski A, Ermak G, Hwang J, Mazurkiewicz J, Corliss D, Eastman A: The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. Biochim Biophys Acta 1996;1289:247–251.
34.
Slominski AJ, Ermak G, Mazurkiewicz JE, Baker J, Wortsman J: Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab 1998;83:1020–1024.
35.
Slominski A, Wortsman J, Luger T, Paus R, Solomon S: Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000;80:979–1020.
36.
Roloff B, Fechner K, Slominski A, Furkert J, Botchkarev VA, Bulfone-Paus S, Zipper J, Krause E, Paus R: Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin. FASEB J 1998;12:287–297.
37.
Toyoda M, Makino T, Kagoura M, Morohashi M: Expression of neuropeptide-degrading enzymes in alopecia areata: An immunohistochemical study. Br J Dermatol 2001;144:46–54.
38.
Conti P, Reale M, Barbacane RC, Letourneau R, Theoharides TC: Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase: Lack of effects in genetically mast cell-deficient W/Wv mice. FASEB J 1998;12:1693–1700.
39.
Theoharides TC: Mast cell: A neuroimmunoendocrine master player. Int J Tissue React 1996;18:1–21.
40.
Botchkarev VA, Eichmuller S, Peters EM, Pietsch P, Johansson O, Maurer M, Paus R: A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycledependent changes in mast cell-nerve fiber contacts in murine skin. Arch Dermatol Res 1997;289:292–302.
41.
Simoncini T, Apa R, Reis FM, Micelli F, Stomati M, Driul L, Lanzone A, Genazzani AR, Petraglia F: Human umbilical vein endothelial cells: A new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999;84:2802–2806.
42.
Clifton VL, Read MA, Leitch IM, Giles WB, Boura ALA, Robinson PJ, Smith R: Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: Involvement of the nitric oxide-cyclic guanosine 3′,5′-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995;80:2888–2893.
43.
Fleisher-Berkovich S, Rimon G, Danon A: Modulation of endothelial prostaglandin synthesis by corticotropin releasing factor and antagonists. Eur J Pharmacol 1998;353:297–302.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.